https://www.nasdaq.com/press-release/amgen-to-present-at-the-goldman-sachs-14th-annual-healthcare-ceos-unscripted
https://www.nasdaq.com/press-release/fda-approves-otezlar-apremilast-for-the-treatment-of-adult-patients-with-plaque
https://www.nasdaq.com/press-release/fda-approves-tezspiretm-tezepelumab-ekko-in-the-u.s.-for-severe-asthma-2021-12-17
https://www.nasdaq.com/press-release/amgen-announces-new-data-being-presented-at-ash-2021-2021-12-06
https://www.nasdaq.com/press-release/amgen-announces-10-increase-in-2022-first-quarter-dividend-2021-12-03
https://www.nasdaq.com/press-release/amgen-announces-positive-top-line-results-from-otezlar-apremilast-phase-3-discreet
https://www.nasdaq.com/press-release/fda-approves-new-kyprolisr-carfilzomib-combination-regimen-with-darzalex-faspror
https://www.nasdaq.com/press-release/amgen-named-to-dow-jones-sustainability-world-index-for-eighth-consecutive-year-2021
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-evercore-isi-healthcare-conference-2021-11-24
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-piper-sandler-healthcare-conference-2021-11-24
https://www.nasdaq.com/press-release/blade-therapeutics-appoints-bassem-elmankabadi-m.d.-as-senior-vice-president-of
https://www.nasdaq.com/press-release/amgen-awards-the-bath-institute-of-rheumatic-diseases-%2425000-through-uplift
https://www.nasdaq.com/press-release/lumykrasr-sotorasib-receives-positive-opinion-from-ema-chmp-for-patients-with-kras
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-annual-cowen-io-summit-2021-11-10
https://www.nasdaq.com/press-release/first-and-only-randomized-double-blind-head-to-head-study-comparing-aimovigr-erenumab
https://www.nasdaq.com/press-release/amgen-begins-construction-on-new-biomanufacturing-plant-in-central-ohio-2021-11-05
https://www.nasdaq.com/press-release/amgen-reports-third-quarter-2021-financial-results-2021-11-02
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2021-third-quarter-financial-results-2021-10-28
https://www.nasdaq.com/press-release/fortune-and-great-place-to-workr-name-amgen-one-of-the-worlds-best-workplacestm-in
https://www.nasdaq.com/press-release/amgen-announces-2021-fourth-quarter-dividend-2021-10-21
https://www.nasdaq.com/press-release/amgen-successfully-completes-acquisition-of-teneobio-inc.-2021-10-19
https://www.nasdaq.com/press-release/amgen-announces-new-lumakrastm-sotorasib-combination-data-from-phase-1b-codebreak-101
https://www.nasdaq.com/press-release/amgen-and-neumora-therapeutics-announce-strategic-rd-collaboration-to-accelerate
https://www.nasdaq.com/press-release/amgen-announces-new-data-highlighting-global-trends-in-hip-fracture-incidence-and
https://www.nasdaq.com/press-release/amgen-and-kyowa-kirin-present-positive-late-breaking-data-from-phase-2-study-of-amg
https://www.nasdaq.com/press-release/kyowa-kirin-and-amgen-present-positive-late-breaking-data-from-phase-2-study-of
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-call-at-eadv-2021-2021-09-29
https://www.nasdaq.com/press-release/fda-approves-repathar-evolocumab-in-pediatric-patients-age-10-and-older-with
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-cantor-global-healthcare-conference-2021-09-22
https://www.nasdaq.com/press-release/amgen-releases-8th-edition-of-biosimilar-trends-report-2021-09-22
https://www.nasdaq.com/press-release/amgen-wins-patent-case-on-otezlar-apremilast-2021-09-20
https://www.nasdaq.com/press-release/lumakrastm-sotorasib-combined-with-vectibixr-panitumumab-showed-encouraging-efficacy
https://www.nasdaq.com/press-release/amgen-and-the-lundquist-institute-announce-that-diadem-therapeuctics-will-receive-the
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-global-healthcare
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-call-at-esmo-2021-2021-09-13
https://www.nasdaq.com/press-release/amgen-to-showcase-new-data-from-inflammation-portfolio-at-eadv-virtual-congress-2021
https://www.nasdaq.com/press-release/kyowa-kirin-to-present-atopic-dermatitis-clinical-data-from-khk4083-amg-451-phase-2-0
https://www.nasdaq.com/press-release/kyowa-kirin-to-present-atopic-dermatitis-clinical-data-from-khk4083-amg-451-phase-2
https://www.nasdaq.com/press-release/amgen-to-present-at-the-19th-annual-morgan-stanley-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/amgen-presents-new-data-from-thoracic-oncology-portfolio-at-wclc21-2021-09-08
https://www.nasdaq.com/press-release/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe
https://www.nasdaq.com/press-release/amgen-to-present-at-the-16th-annual-citi-biopharma-conference-2021-09-03
https://www.nasdaq.com/press-release/new-data-at-esc-congress-2021-shows-repathar-evolocumab-improves-features-of-plaque
https://www.nasdaq.com/press-release/amgen-reports-second-quarter-2021-financial-results-2021-08-03
https://www.nasdaq.com/press-release/american-kidney-fund-launches-kidney-kitchen-protm-to-expand-patient-nutrition
https://www.nasdaq.com/press-release/amgen-announces-2021-third-quarter-dividend-2021-07-30
https://www.nasdaq.com/press-release/amgen-appoints-s.-omar-ishrak-to-board-of-directors-2021-07-29
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2021-second-quarter-financial-results-2021-07-29
https://www.nasdaq.com/press-release/amgen-to-acquire-privately-held-teneobio-for-%24900-million-in-cash-with-future
https://www.nasdaq.com/press-release/decode-genetics-new-study-on-inheritance-and-fetal-growth-2021-07-19
https://www.nasdaq.com/press-release/amgen-and-the-international-federation-of-psoriasis-associations-launch-uplift
https://www.nasdaq.com/press-release/tezepelumab-granted-priority-review-by-u.s.-fda-2021-07-08
https://www.nasdaq.com/press-release/labcorp-launches-companion-diagnostic-for-amgens-newly-approved-lung-cancer-therapy
https://www.nasdaq.com/press-release/amgen-announces-approval-of-aimovigr-erenumab-in-japan-for-the-suppression-of-onset
https://www.nasdaq.com/press-release/acclaimed-makeup-artist-allan-avendano-opens-up-about-personal-skin-condition%3a
https://www.nasdaq.com/press-release/amgen-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/results-from-phase-2-codebreak-100-show-lumakrastm-sotorasib-is-the-first-and-only
https://www.nasdaq.com/press-release/phase-2-fight-trial-continues-to-show-improved-overall-survival-with-bemarituzumab
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-meeting-at-asco-2021-2021-06-01
https://www.nasdaq.com/press-release/amgen-and-kyowa-kirin-to-jointly-develop-and-commercialize-khk4083-a-phase-3-ready
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-jefferies-healthcare-conference-2021-05-28
https://www.nasdaq.com/press-release/fda-approves-lumakrastm-sotorasib-the-first-and-only-targeted-treatment-for-patients
https://www.nasdaq.com/press-release/amgen-to-present-at-the-cowen-2nd-annual-virtual-oncology-innovation-summit-2021-05
https://www.nasdaq.com/press-release/amgen-to-showcase-new-data-from-oncology-portfolio-at-asco-2021-2021-05-19
https://www.nasdaq.com/press-release/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe
https://www.nasdaq.com/press-release/efficacy-of-repathar-evolocumab-across-high-risk-patient-populations-reinforced-at
https://www.nasdaq.com/press-release/amgen-announces-tezepelumab-biologics-license-application-submitted-to-u.s.-fda-2021
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-healthcare-conference-2021
https://www.nasdaq.com/press-release/fda-accepts-amgens-supplemental-new-drug-application-for-otezlar-apremilast-for
https://www.nasdaq.com/press-release/amgen-provides-updated-information-on-lumakrastm-sotorasib1-dose-comparison-study
https://www.nasdaq.com/press-release/amgen-reports-first-quarter-2021-financial-results-2021-04-27
https://www.nasdaq.com/press-release/otezlar-apremilast-significantly-improved-measures-of-disease-severity-in-adults-with
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2021-first-quarter-financial-results-2021-04-22
https://www.nasdaq.com/press-release/amgens-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy
https://www.nasdaq.com/press-release/amgen-launches-biomarker-assisttm-a-program-to-help-more-patients-with-non-small-cell
https://www.nasdaq.com/press-release/amgen-successfully-completes-acquisition-of-five-prime-therapeutics-2021-04-16
https://www.nasdaq.com/press-release/amgen-to-acquire-rodeo-therapeutics-corporation-2021-03-30
https://www.nasdaq.com/press-release/cardiol-therapeutics-appoints-dr.-andrew-hamer-as-new-chief-medical-officer-2021-03
https://www.nasdaq.com/press-release/amgen-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-2021-03-11
https://www.nasdaq.com/press-release/amgen-to-acquire-five-prime-therapeutics-for-%241.9-billion-in-cash-2021-03-04-0
https://www.nasdaq.com/press-release/amgen-to-acquire-five-prime-therapeutics-for-%241.9-billion-in-cash-2021-03-04
https://www.nasdaq.com/press-release/amgen-announces-2021-second-quarter-dividend-2021-03-03
https://www.nasdaq.com/press-release/blincytor-blinatumomab-demonstrated-significantly-prolonged-event-free-survival
https://www.nasdaq.com/press-release/tezepelumab-is-the-first-biologic-to-significantly-reduce-exacerbations-in-broad
https://www.nasdaq.com/press-release/amgen-to-present-at-the-cowen-41st-annual-healthcare-conference-2021-02-24
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-meeting-at-aaaai-virtual-annual-meeting-2021-02-22
https://www.nasdaq.com/press-release/amgen-submits-supplemental-new-drug-application-for-otezlar-apremilast-for-adults
https://www.nasdaq.com/press-release/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with
https://www.nasdaq.com/press-release/amgen-to-present-at-guggenheim-healthcare-talks-oncology-day-2021-02-09
https://www.nasdaq.com/press-release/amgen-sponsors-golden-ticket-at-biolabs-la-at-the-lundquist-institute-to-help
https://www.nasdaq.com/press-release/amgen-reports-fourth-quarter-and-full-year-2020-financial-results-2021-02-02
https://www.nasdaq.com/press-release/amgen-announces-breakthrough-therapy-designation-granted-for-sotorasib-in-china-2021
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2020-fourth-quarter-and-full-year-financial-results-2021
https://www.nasdaq.com/press-release/amgens-investigational-kras-g12c-inhibitor-sotorasib-demonstrated-rapid-deep-and
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-meeting-at-2020-world-conference-on-lung-cancer-2021-01-26
https://www.nasdaq.com/press-release/amgen-to-showcase-next-frontier-of-innovation-in-lung-cancer-therapies-at-wclc-2020
https://www.nasdaq.com/press-release/jose-m.-vega-m.d.-joins-moderna-as-chief-safety-officer-2021-01-12
https://www.nasdaq.com/press-release/amgen-to-achieve-carbon-neutrality-by-2027-2021-01-11
https://www.nasdaq.com/press-release/grail-announces-collaborations-with-amgen-astrazeneca-and-bristol-myers-squibb-to
https://www.nasdaq.com/press-release/amgen-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-06
https://www.nasdaq.com/press-release/amgen-licenses-amg-634-an-investigational-treatment-for-tuberculosis-and-leprosy-to
https://www.nasdaq.com/press-release/amgen-submits-sotorasib-marketing-authorization-application-to-the-european-medicines
https://www.nasdaq.com/press-release/update-on-source-phase-3-trial-for-tezepelumab-in-patients-with-severe-oral
https://www.nasdaq.com/press-release/amgen-awards-two-local-biotech-start-ups-with-golden-ticket-to-labcentral-2020-12-17
https://www.nasdaq.com/press-release/fda-approves-amgens-riabnitm-rituximab-arrx-a-biosimilar-to-rituxanr-rituximab-2020
https://www.nasdaq.com/press-release/amgen-to-transfer-listing-of-debt-securities-to-nasdaq-2020-12-16
https://www.nasdaq.com/press-release/amgen-announces-10-increase-in-2021-first-quarter-dividend-2020-12-16
https://www.nasdaq.com/press-release/amgen-submits-sotorasib-new-drug-application-to-u.s.-fda-for-advanced-or-metastatic
https://www.nasdaq.com/press-release/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic
https://www.nasdaq.com/press-release/amgen-and-novartis-partner-with-karamo-brown-to-support-and-empower-people-living
https://www.nasdaq.com/press-release/amgen-to-present-first-clinical-data-for-bcma-targeted-half-life-extended-biter
https://www.nasdaq.com/press-release/amgen-and-mckesson-launch-strategic-agreement-to-advance-cancer-innovation-in
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-call-at-ash-2020-2020-12-03
https://www.nasdaq.com/press-release/worlds-leading-life-science-companies-now-enrolling-community-a-global-platform-trial
https://www.nasdaq.com/press-release/amgen-announces-new-data-being-presented-at-ash-2020-2020-11-30
https://www.nasdaq.com/press-release/amgen-to-present-at-the-evercore-isi-virtual-healthconx-conference-2020-11-25
https://www.nasdaq.com/press-release/amgen-to-transition-development-and-commercial-rights-for-omecamtiv-mecarbil-and-amg
https://www.nasdaq.com/press-release/amgen-to-present-at-the-jefferies-virtual-london-healthcare-conference-2020-11-13
https://www.nasdaq.com/press-release/amgen-to-present-at-the-cowen-4th-annual-io-summit-2020-11-10
https://www.nasdaq.com/press-release/tezepelumab-navigator-phase-3-trial-met-primary-endpoint-of-a-statistically
https://www.nasdaq.com/press-release/amgen-showcases-new-data-across-cardiovascular-portfolio-at-aha-scientific-sessions
https://www.nasdaq.com/press-release/amgen-presents-first-clinical-data-for-amg-757-at-sitc-2020-2020-11-09
https://www.nasdaq.com/press-release/amgen-to-present-at-the-29th-annual-credit-suisse-healthcare-conference-2020-11-04
https://www.nasdaq.com/press-release/amgen-reports-third-quarter-2020-financial-results-2020-10-28
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2020-third-quarter-financial-results-2020-10-27
https://www.nasdaq.com/press-release/amgen-announces-participation-of-systemic-lupus-erythematosus-sle-adaptive-clinical
https://www.nasdaq.com/press-release/amgen-announces-2020-fourth-quarter-dividend-2020-10-21
https://www.nasdaq.com/press-release/amgen-cytokinetics-and-servier-announce-topline-results-from-galactic-hf-a-phase-3-0
https://www.nasdaq.com/press-release/amgen-cytokinetics-and-servier-announce-topline-results-from-galactic-hf-a-phase-3
https://www.nasdaq.com/press-release/amgen-announces-positive-topline-phase-2-results-for-investigational-kras-g12c
https://www.nasdaq.com/press-release/amgen-announces-five-year-data-that-reinforce-the-safety-and-efficacy-profile-of
https://www.nasdaq.com/press-release/clinical-data-from-full-phase-1-cohort-of-investigational-sotorasib-published-in-new
https://www.nasdaq.com/press-release/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-calls-at-esmo-2020-2020-09-16
https://www.nasdaq.com/press-release/amgen-to-showcase-data-from-oncology-pipeline-during-esmo-virtual-congress-2020-2020
https://www.nasdaq.com/press-release/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket-2020-09-15
https://www.nasdaq.com/press-release/amgen-to-present-at-the-2020-bank-of-america-virtual-global-healthcare-conference
https://www.nasdaq.com/press-release/amgen-to-present-at-the-18th-annual-morgan-stanley-global-healthcare-conference-2020
https://www.nasdaq.com/press-release/amgen-to-present-at-the-15th-annual-citi-biopharma-conference-2020-09-04
https://www.nasdaq.com/press-release/humoral-immune-response-to-sars-cov2-in-iceland-2020-09-01
https://www.nasdaq.com/press-release/amgen-announces-positive-data-from-phase-3b-study-of-repathar-evolocumab-in-pediatric
https://www.nasdaq.com/press-release/new-amgen-data-to-be-presented-at-esc-congress-2020-highlighting-repathar-evolocumab
https://www.nasdaq.com/press-release/salesforce.com-amgen-and-honeywell-international-set-to-join-dow-jones-industrial
https://www.nasdaq.com/press-release/ligand-announces-amgens-kyprolisr-approved-by-fda-as-combination-regimen-with
https://www.nasdaq.com/press-release/fda-approves-new-kyprolisr-carfilzomib-combination-regimen-with-darzalexr-daratumumab
https://www.nasdaq.com/press-release/amgen-announces-pricing-terms-for-senior-notes-exchange-offers-increases-the-maximum
https://www.nasdaq.com/press-release/amgen-announces-early-tender-results-of-senior-notes-exchange-offers-2020-08-13
https://www.nasdaq.com/press-release/dietary-cholesterol-and-phytosterols-contribute-directly-to-heart-disease-2020-08-06
https://www.nasdaq.com/press-release/members-of-the-covid-rd-alliance-and-quantum-leap-healthcare-collaborative-enroll
https://www.nasdaq.com/press-release/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from
https://www.nasdaq.com/press-release/amgen-reports-second-quarter-2020-financial-results-2020-07-28
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2020-second-quarter-financial-results-2020-07-23
https://www.nasdaq.com/press-release/amgen-announces-2020-third-quarter-dividend-2020-07-23
https://www.nasdaq.com/press-release/amgen-appoints-amy-e.-miles-to-board-of-directors-2020-07-23
https://www.nasdaq.com/press-release/the-us-australia-and-canada-lead-but-no-g20-country-is-fully-prepared-for-the-needs
https://www.nasdaq.com/press-release/amgen-foundation-awards-khan-academy-an-additional-%243-million-to-support-science
https://www.nasdaq.com/press-release/amgen-announces-additional-investment-in-beigene-2020-07-12
https://www.nasdaq.com/press-release/amgen-announces-global-diagnostic-collaborations-to-expand-molecular-testing-for
https://www.nasdaq.com/press-release/amgen-to-present-at-the-goldman-sachs-12th-annual-healthcare-ceos-unscripted
https://www.nasdaq.com/press-release/amgen-and-allergan-submit-biologics-license-application-for-abp-798-biosimilar
https://www.nasdaq.com/press-release/european-commission-approves-evenityr-romosozumab-for-the-treatment-of-severe
https://www.nasdaq.com/press-release/beyond-cholesterol%3a-landmark-decode-study-elucidates-role-of-lipoproteina-as-major
https://www.nasdaq.com/press-release/amgen-selects-location-for-rd-facility-in-the-south-san-francisco-biotechnology-hub
https://www.nasdaq.com/press-release/fda-approves-amgens-avsolatm-infliximab-axxq-for-the-same-indications-as-remicader
https://www.nasdaq.com/press-release/abarca-amgen-enter-outcome-based-agreement-for-enbrel-2019-12-03
https://www.nasdaq.com/press-release/amgen-announces-data-being-presented-at-ash-2019-2019-12-02
https://www.nasdaq.com/press-release/thinking-about-trading-options-or-stock-in-amgen-the-medicines-company-netflix-nvidia
https://www.nasdaq.com/press-release/amgen-completes-acquisition-of-otezlar-apremilast-2019-11-21
https://www.nasdaq.com/press-release/new-results-from-cosmic-hf-presented-at-aha-2019-show-treatment-of-heart-failure
https://www.nasdaq.com/press-release/amgen-announces-new-fourier-analysis-showing-benefit-of-repathar-evolocumab-in-high
https://www.nasdaq.com/press-release/amgen-and-the-duke-clinical-research-institute-announce-initiation-of-first-large
https://www.nasdaq.com/press-release/amgen-highlights-data-to-be-presented-at-aha-2019-across-cardiovascular-portfolio
https://www.nasdaq.com/press-release/amgen-to-present-at-the-28th-annual-credit-suisse-healthcare-conference-2019-11-07
https://www.nasdaq.com/press-release/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in
https://www.nasdaq.com/press-release/the-discovery-of-amgens-novel-investigational-krasg12c-inhibitor-amg-510-published-in
https://www.nasdaq.com/press-release/amgen-reports-third-quarter-2019-financial-results-2019-10-29
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2019-third-quarter-financial-results-2019-10-24
https://www.nasdaq.com/press-release/amgen-to-make-repathar-evolocumab-available-exclusively-at-its-lower-list-price
https://www.nasdaq.com/press-release/amgen-recommends-rejection-of-mini-tender-offer-from-trc-capital-corporation-2019-10
https://www.nasdaq.com/press-release/david-meline-amgens-chief-financial-officer-to-retire-2019-10-22
https://www.nasdaq.com/press-release/amgen-announces-2019-fourth-quarter-dividend-2019-10-22
https://www.nasdaq.com/press-release/nplater-romiplostim-now-approved-for-earlier-use-in-adults-with-immune
https://www.nasdaq.com/press-release/evenityr-romosozumab-receives-positive-chmp-opinion-for-the-treatment-of-severe
https://www.nasdaq.com/press-release/sports-anchor-and-multiple-myeloma-patient-rod-gilmore-joins-amgens-myeloma-mvptm
https://www.nasdaq.com/press-release/amgen-foundation-launches-amgen-biotech-experience-in-pittsburgh-2019-10-09
https://www.nasdaq.com/press-release/amgen-announces-new-clinical-data-evaluating-novel-investigational-krasg12c-0
https://www.nasdaq.com/press-release/amgen-announces-positive-results-from-two-phase-3-blincytor-blinatumomab-studies-in
https://www.nasdaq.com/press-release/amgen-showcases-new-data-from-oncology-pipeline-and-portfolio-at-esmo-2019-2019-09-17
https://www.nasdaq.com/press-release/sp-500-buybacks-decline-significantly-in-q2-2019-expenditures-still-remain-higher
https://www.nasdaq.com/press-release/amgen-announces-new-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor
https://www.nasdaq.com/press-release/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-2019-09-05
https://www.nasdaq.com/press-release/amgen-to-webcast-investor-call-at-iaslc-2019-world-conference-on-lung-cancer-2019-09
https://www.nasdaq.com/press-release/new-amgen-data-to-be-presented-at-esc-congress-2019-highlight-additional-evidence-for
https://www.nasdaq.com/press-release/amgen-to-acquire-otezlar-for-%2413.4-billion-in-cash-or-approximately-%2411.2-billion-net
https://www.nasdaq.com/press-release/amgen-and-allergan-announce-positive-top-line-results-from-comparative-clinical-study
https://www.nasdaq.com/press-release/amgen-wins-patent-case-on-enbrelr-etanercept-2019-08-09
https://www.nasdaq.com/press-release/amgen-announces-2019-third-quarter-dividend-2019-08-02
https://www.nasdaq.com/press-release/amgen-controls-98-of-the-shares-in-nuevolution-after-the-end-of-the-extended
https://www.nasdaq.com/press-release/amgen-announces-webcast-of-2019-second-quarter-financial-results-2019-07-25
https://www.nasdaq.com/press-release/amgen-and-allergans-mvasitm-bevacizumab-awwb-and-kanjintitm-trastuzumab-anns-now
https://www.nasdaq.com/press-release/amgen-novartis-and-banner-alzheimers-institute-discontinue-clinical-research-program
https://www.nasdaq.com/press-release/amgen-announces-the-outcome-of-the-recommended-public-cash-offer-to-the-shareholders
https://www.nasdaq.com/press-release/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket-2019-06-25
https://www.nasdaq.com/press-release/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce
https://www.nasdaq.com/press-release/amgen-announces-blincytor-blinatumomab-five-year-overall-survival-data-at-eha-2019
https://www.nasdaq.com/press-release/fda-approves-amgen-and-allergans-kanjintitm-trastuzumab-anns-a-biosimilar-to
https://www.nasdaq.com/press-release/amgen-publishes-offer-document-respect-recommended-public-cash-offer-shareholders
https://www.nasdaq.com/press-release/amgen-present-goldman-sachs-40th-annual-global-healthcare-conference-2019-06-07
https://www.nasdaq.com/press-release/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c
https://www.nasdaq.com/press-release/amgen-highlights-versatility-biter-immuno-oncology-platform-multiple-tumor-types-asco
https://www.nasdaq.com/press-release/amgen-webcast-investor-meeting-55th-annual-meeting-american-society-clinical-oncology
https://www.nasdaq.com/press-release/additional-irrevocable-undertakings-accept-amgens-recommended-public-cash-offer
https://www.nasdaq.com/press-release/amgen-joins-community-oncology-networks-new-research-collaboration-2019-05-28
https://www.nasdaq.com/press-release/amgen-announces-recommended-public-cash-offer-shareholders-nuevolution-2019-05-22
https://www.nasdaq.com/press-release/amgen-present-rbc-healthcare-conference-and-ubs-global-healthcare-conference-2019-05
https://www.nasdaq.com/press-release/amgen-present-bank-america-merrill-lynch-2019-health-care-conference-2019-05-10
https://www.nasdaq.com/press-release/amgen-highlight-extensive-long-term-safety-and-efficacy-data-aimovigr-erenumab-aooe
https://www.nasdaq.com/press-release/amgen-and-syapse-enter-precision-medicine-collaboration-oncology-2019-05-02
https://www.nasdaq.com/press-release/amgen-ignites-social-fitness-movement-support-fight-against-heart-disease-and-cancer
https://www.nasdaq.com/press-release/amgen-announces-webcast-2019-first-quarter-financial-results-2019-04-25
https://www.nasdaq.com/press-release/amgen-foundation-launches-amgen-biotech-experience-tampa-florida-2019-04-17
https://www.nasdaq.com/press-release/evenitytm-romosozumab-aqqg-now-available-united-states-treatment-osteoporosis-0
https://www.nasdaq.com/press-release/evenitytm-romosozumab-aqqg-now-available-united-states-treatment-osteoporosis
https://www.nasdaq.com/press-release/fda-approves-evenitytm-romosozumab-aqqg-treatment-osteoporosis-postmenopausal-women
https://www.nasdaq.com/press-release/fda-approves-evenitytm-romosozumab-aqqg-treatment-osteoporosis-postmenopausal-women-0
https://www.nasdaq.com/press-release/amgen-presents-new-data-wco-iof-esceo-2019-revealing-osteoporosis-treatment-gap
https://www.nasdaq.com/press-release/sp-500-q4-2018-buybacks-set-4th-consecutive-quarterly-record-223-billion-2018-sets
https://www.nasdaq.com/press-release/amgen-cytokinetics-and-servier-announce-continuation-galactic-hf-following-planned
https://www.nasdaq.com/press-release/amgen-announces-new-four-year-outcomes-study-examine-long-term-effects-repathar
https://www.nasdaq.com/press-release/industry-veteran-joins-vivacitas-oncology-new-biotech-ceo-2019-04-21
https://www.nasdaq.com/press-release/amgen-and-jay-leno-partner-sound-alarm-high-cholesterol-and-its-link-heart-attack-and
https://www.nasdaq.com/press-release/amgen-announces-2019-second-quarter-dividend-2019-04-21
https://www.nasdaq.com/press-release/amgen-present-cowen-and-company-39th-annual-healthcare-conference-2019-04-21
https://www.nasdaq.com/press-release/prominent-cardiovascular-expert-james-j-ferguson-md-facc-faha-joins-matinas-biopharma
https://www.nasdaq.com/press-release/amgen-cytokinetics-and-servier-announce-start-meteoric-hf-second-phase-3-clinical
https://www.nasdaq.com/press-release/molecular-partners-reports-key-financials-fy-2018-and-corporate-highlights-q4-2018
